Notably, mTOR inhibitors have been widely used in the treatment of neuroendocrine tumors (NETs), for example, everolimus has been approved in pancreatic, gastrointestinal and lung NETs62. This evidence concerns the gene MTOR and neuroendocrine neoplasm.